Category Archives: Genetic Engineering

Company provides summary business update and 2022 preview

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Eric Ostertag as Executive Chairman and the transition of current President and Chief Business Officer, Mark Gergen, to the role of Chief Executive Officer effective as of February 1, 2022. The Company also provided a summary business update and 2022 preview.

Poseida Therapeutics (PRNewsfoto/Poseida Therapeutics, Inc.)

Poseida announces President Mark Gergen to serve as CEO, effective 2/1. Eric Ostertag named Executive Chairman. $PSTX

"For the last four years, Mark and I have worked closely to build Poseida into the organization it is today, making tremendous progress on a wide variety of initiatives which includes taking the company public in 2020, and preparing for the next wave of growth that lies ahead," said Eric Ostertag, M.D., Ph.D., Chief Executive Officer of Poseida Therapeutics. "Going forward, Mark will assume the overall leadership of the company while I will focus on high-level strategy, intended to maximize the value of our differentiated genetic engineering platforms and product candidates. In addition to continuing to chair the board of directors, I will also work to expand and further develop our scientific advisory boards."

As Poseida's founder and CEO, Ostertag directed the Company's spin out in early 2015 from parent company Transposagen Biopharmaceuticals, Inc., a biotechnology company that commercialized gene editing technology in research applications. Ostertag also founded Transposagen, where he was CEO from 2003 to 2015. Ostertag earned his M.D. and Ph.D. from the University of Pennsylvania. Under his leadership, Poseida grew to over 250 employees, raised significant private capital and successfully completed an IPO in 2020. The Company has also built a significant global intellectual property portfolio; received FDA clearance on four Investigational New Drug (IND) applications for novel cell therapies, dosing over 100 patients in clinical trials; and established multiple collaborations, including the recently announced gene therapy collaboration with Takeda Pharmaceutical Company Limited ("Takeda"), which has a potential total value of up to $3.6 billion.

Story continues

"It is a privilege to take on the role of CEO and lead the organization as we continue our progress toward our mission to redefine cell and gene therapy. The partnership Eric and I have built in guiding the company will continue," said Mark Gergen, Poseida's President and Chief Business Officer. "I am very excited about 2022 and the opportunities we will have to differentiate our platforms in both cell and gene therapy. We are highly focused on getting to key inflection points on our solid tumor and allogeneic CAR-T programs as well as advancing our gene therapy efforts, including those associated with our recent collaboration with Takeda."

Gergen joined Poseida in February 2018, serving as Chief Business Officer and Chief Financial Officer before being appointed President and Chief Business Officer in July 2020. During his career in the biotech and pharmaceutical industries, Gergen has provided strategic leadership to companies as they scale, grow, and execute on the promise of their technologies. Before joining Poseida, he held key leadership roles including that of Senior Vice President and Chief Operating Officer of Halozyme, Inc., Executive Vice President and Chief Operating Officer at Mirati Therapeutics, Inc. and as Senior Vice President of Corporate Development at Amylin Pharmaceuticals, Inc. He has also served in senior management positions at CardioNet Inc., Advanced Tissue Sciences, Inc., and Medtronic, Inc. Gergen received a J.D. from the University of Minnesota Law School and a B.A. in business administration from Minot State University in North Dakota.

Both Ostertag and Gergen will continue to serve as members of the Company's Board of Directors.

Business Update and 2022 Preview

Annual R&D DayThe Company will soon host its second annual R&D Day, scheduled for Wednesday, February 23, 2022. Dr. Ostertag will lead the event, featuring presentations highlighting the current product pipeline, advancements in early discovery and research programs, and detailing novel next generation approaches and technology applications. To register for the webcast, please visit the Investor Relations section of the Poseida website.

P-PSMA-101 Autologous CAR-T for Prostate CancerA Phase 1 trial evaluating P-PSMA-101, the Company's autologous CAR-T candidate for the treatment of metastatic castrate resistant prostate cancer (mCRPC) is ongoing. Initial clinical data was presented in late August 2021 at the CAR-TCR Summit demonstrating encouraging early results at low doses in this difficult to treat patient population with high unmet need. The Company will be presenting additional data during the ASCO Genitourinary Cancers Symposium taking place February 17-19, 2022, in a poster titled, "Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)."

P-BCMA-ALLO1 Allogeneic CAR-T for R/R Multiple MyelomaThe Phase 1 trial of P-BCMA-ALLO1, an allogeneic CAR-T product candidate for the treatment of relapsed refractory multiple myeloma, is currently initiating with a clinical data update expected later in the year. In addition to the continued product manufacturing at the current contract manufacturing organization, the Company is exploring a parallel path to enable manufacturing of P-BCMA-ALLO1 at its in-house GMP manufacturing pilot plant in San Diego, following successful manufacturing runs of the allogeneic CAR-T product candidate P-MUC1C-ALLO1.

P-MUC1C-ALLO1 Allogeneic CAR-T for Solid Tumors The Company announced on December 20, 2021 that the IND submitted for the P-MUC1C-ALLO1 product candidate had been cleared by the FDA. The Phase 1 clinical trial start-up is underway and will evaluate P-MUC1C-ALLO1 in various solid tumors, including breast, ovarian, lung and colorectal cancers. P-MUC1C-ALLO1 is manufactured at the Company's in-house GMP manufacturing pilot plant in San Diego. Initial clinical data from P-MUC1C-ALLO1 is expected to be presented at a scientific meeting this year.

Dual P-CD19CD20-ALLO1 Allogeneic Car T for B-cell MalignanciesDue to the prioritization of the lead allogeneic programs and the focus on achieving associated milestones in 2022, the Company is shifting expectations for an IND filing of its first dual CAR-T program from the end of 2022 into 2023.

P-OTC-101 In Vivo Liver Directed Gene Therapy for OTCThe Company's leading internal gene therapy program, P-OTC-101, an in vivo liver-directed gene therapy for ornithine transcarbamylase (OTC) deficiency, continues with IND enabling activities and evaluation of both a fully nanoparticle delivery approach as well as a hybrid nanoparticle/AAV approach. A decision of whether to pursue the fully nanoparticle or hybrid approach going forward is expected by mid-year.

Partnerships and CollaborationsThe Company's research collaboration with Takeda focused on nonviral in vivo liver- and HSC- directed gene therapies is underway. The collaboration, announced in October 2021, provides validation of Poseida's genetic engineering technology and approach. In 2022, the Company will continue to evaluate and explore additional opportunities for collaboration and partnership enabled by the breadth and versatility of the piggyBac, Cas-CLOVER, nanoparticle and other technology platforms.

About Poseida Therapeutics, Inc.Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit http://www.poseida.com and connect with us on Twitter and LinkedIn.

Forward-Looking StatementStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential benefits of Poseida's technology platforms and product candidates, Poseida's plans and strategy with respect to developing its technologies and product candidates, future roles and contributions of Poseida's executive officers, and anticipated timelines and milestones with respect to Poseida's development programs and manufacturing activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statement contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-eric-ostertag-to-serve-as-executive-chairman-and-transition-role-of-ceo-to-current-president-and-cbo-mark-gergen-301456644.html

SOURCE Poseida Therapeutics, Inc.

See more here:
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen -...

Opaque land ownership rights engender corruption. Opposing organizations Greenpeace and Cato should unite in canvasing for the adoption of a blockchain register countering dead capital.

Greenpeace is one of the worlds most influential non-governmental organizations. With offices in 55 countries, several thousand staff, and a budget in the hundreds of millions of Euros range, it is committed to campaigning against climate change, deforestation, commercial whaling, genetic engineering and the nuclear industry.

The Cato Institute, by contrast, is much smaller: Just 100 staff (plus 46 faculty and 70 adjunct faculty) and an operating budget of around $31 million. It was founded by the Koch brothers and is committed to free markets and other libertarian causes.

These two groups do not often agree with each other, but when they do, it is worth taking note of what they are saying.

I was interviewing Rolf Skar, Special Projects Manager at Greenpeace who directs the organizations forestry campaigns. He told me something which sounded as though it could have come straight from the Cato Institute and, in particular, from Catos Nobel Prize-winning economist, Hernando de Soto.

Skar argued that one of the biggest problems, and biggest contributions to deforestation in Indonesia is lack of transparency around land ownership rights. Theres no single map defining land ownership, and the system has become hopelessly corrupted.

Any official with a Sharpie can change the map. This corruption allows small landowners to be bulldozed aside with no recourse to defending their rights in court. He suggested the situation was similar in Brazil, and, no doubt, in many other countries.

Poorly defined ownership rights create what economists call dead capital. This is something to which people have a de facto claim, but not one that is backed up in law. De Soto estimated in 2015 that around 5.3 billion people own almost $10 Trillion in dead capital.

Examples of dead capital include land where ownership records are unclear or contradictory, or where there is no legal recourse to enforce ownership rights.

Other examples include informal dwellings built on land that is not designated for residential building.

This happens in heavily regulated cities in developed countries but is far more widespread in the developing world. Market traders respect each others ownership of a particular roadside pitch or timeslot in lieu of a formal record of ownership.

Without official title, these owners cannot sell or bequeath their assets nor can they borrow money secured against their ownership. Theres no opportunity for their enterprises to grow fracturing the cascade of wealth between the generations.

Corruption and incompetence in administration is leading governments on every continent to fail in one of their foremost duties: protecting the rights of people to build better lives for their families.

Massive devastation of the worlds forests is just one of the consequences. Trapping people in poverty and the destruction of indigenous peoples follow from the same inability to protect land rights.

When such opposing organizations as Greenpeace and the Cato Institute are aligned on their analysis of the problem, there must be potential for cooperation: a manifesto or charter for land rights that both can endorse.

This, then, is the challenge: Can Greenpeace and the Cato Institute come together to negotiate such a manifesto? It would be a statement of the problem alongside an outline of steps which governments can take to solve the problems.

Any 21st century solution to the problem of poorly defined ownership rights is likely to be built on incorruptible, probably non-governmental platforms.

An unhackable blockchain property rights register can operate entirely outside the control of corruptible officials.

Since we are seeking a decentralized system, it makes sense to get it adopted in a few countries first. The early adopters will benefit from early investment and a smoother transition to a functioning economy, but later adopters may benefit from tweaks to the technology.

Indonesia is the fourth-largest country in the world by population and 14th by land area. Brazil is the sixth-largest by population and fifth by area, so these two should be enough to be going on with.

Corruption is an insidious cancer which corrodes cooperation and sews cynicism. It tilts power and wealth away from voluntary exchange towards force and coercion.

Rainforests are home to the trees which sequester carbon, the biodiversity which promises future pharmacological breakthroughs and previously undisturbed indigenous peoples. Corruption of land records threatens all of this.

For the first time, technology offers a solution to the problem that devastates the environment and blights the prospects of some 70% of the worlds people.

The practical experience and the moral weight of Greenpeace and Cato can map a path to the solution.

Read more:
Where Greenpeace and Cato Align - The Globalist

To understand the effects of circadian phase on mice behavior, 24 mice were divided into two groups when 4week-old (active phase: mice were maintained in reverse light; inactive phase: mice were maintained in normal light). All mice (8week-old) during the active and inactive phases were subjected to a battery of behavioral tests (initial test), including: rotarod, von Frey test, open field, elevated-O-maze, lightdark box, water maze, T-maze, contextual fear conditioning, and active avoidance. To further confirm the results at a different age, all the behaviors were repeated again three months later (retest, 20week-old) (Fig.1A). Behavioral testing was started two hours after lights on/off; Zeitgeber Time (ZT) 14 for the active group and Zeitgeber Time (ZT) 2 for the inactive group. Ten minutes before the test, tested cages were relocated from animal room to the waiting hallway (red dim light, 15lx) to minimize the effect of light (Fig.1B). Tests were then conducted under the following light intensities: open field (400lx), elevated-O-maze (350lx), lightdark box (440lx), water maze (440lx), T-maze (400lx), contextual fear conditioning (inside the dark box), and active avoidance (inside the dark box).

Effects of diurnal phase on motor coordination and sensory stimulation. (A) Time course of the experimental procedure. Two groups of mice (n=12; 6 males and 6 females in each group) were housed in normal light and reverse light condition. Behavioral tests were conduct 2h after lights on/off (ZT 2 for inactive group, and ZT 14 for active group). (B) The relative position of animal rooms (one reverse light, one normal light) and behavioral testing rooms of the animal house unit. (C) Illustration of rotarod test (left), there is no difference detected in the latency to fall between active group and inactive group in neither the initial test (middle), nor the retest 3months later (right). (D) For von Frey test, mice tested in the active phase exhibit a slightly more sensitive in cutaneoussensory testing than mice tested in the inactive phase in the initial tests. Three months later, mice tested in the active phase still exhibit more sensitivity to filament stimulus compared to mice tested in inactive phase. Blue circles: male mice; Red circles: female mice.

To test the influence of the lightdark cycle on motor coordination and sensory stimuli, mice were subjected to the rotarod and von Frey tests. Our results show that there are no differences on the latency to fall in the rotarod test between inactive and active groups in the initial test (p=0.54, t(22)=0.61), nor the retest three months later (p=0.94, t(22)=0.07) (Fig.1C). Next, to assess sensitivity to sensory stimuli, all mice were subjected to the von Frey test; a mechanicalstimulationbya filament to hind paws. Mice tested in the inactive phase are slightly less sensitive in the initial test (p=0.049, F(1,44)=4.06). For the retest three months later, the results are similar to the initial test, mice tested in inactive phase are still less sensitive than tested in active phase (p=0.0085, F(1,44)=7.59) (Fig.1D). These results suggest that the performance of motor coordination and balance is not influenced by diurnal activity, but cutaneoussensitivity is more responsive in the active phase.

To better understand the effects of diurnal rhythm on anxiety, we chose three common tests associated with anxiety like behavior: the open field test, elevated-O-maze, and lightdark box. All mice were subjected to these three tests. Our results show that there were no significant differences detected between inactive and active groups in the open field test in the initial test (travel distance, p=0.25, t(22)=1.17; time in center zone, p=0.09, t(22)=1.72), nor the retest three months later (travel distance, p=0.89, t(22)=0.13; time in center zone, p=0.57, t(22)=0.56) (Fig.2A). For the elevated-O-maze test, there were no significant difference detected in the initial test (travel distance, p=0.244, t(22)=1.19; during in the open arms, p=0.11, t(22)=1.64). However, mice tested in inactive period showed higher travel distance (p=0.01, t(22)=2.62) and exhibited a trend to stay longer in the open arms (p=0.06, t(22)=1.94) in the retest (Fig.2B). Next, we subjected all the mice to the lightdark box test, in the initial test there were no differences in time spent in the light compartment: p=0.75, t(22)=0.31). Three months later, all mice were subjected to the tests again. Mice tested in the inactive period spent more time in the light compartment (p=0.036, t(22)=2.23) (Fig.2C). The results show that there were no remarkable differences observed in anxiety tests while testing mice during active or inactive periods in the first test. However, three months later upon retesting, we did observe that mice exhibited less travel distance in the elevated-O-maze and spent less time in the light compartment.

Effects of diurnal phase on anxiety tests. (A) There is no significant difference in distance traveled or time spent in the center zone of open field between active and inactive groups in the initial test, nor in the retest 3months later. (B) In the elevated-O-maze, there is no significant difference detected in distance travel or times spent in the open arms between active and inactive groups. However, 3months later, the mice from the inactive group travelled a higher distance, but with no significant difference in time spent in the open arms in the retest. (C) In the lightdark box, there is no significant difference in time spent in the light box in the initial test. In the retest 3months later, mice tested in active phase spent less time in the light compartment. Blue circles: male mice; Red circles: female mice.

It is unclear whether a time-of-day may influence the performance of spatial learning and memory. To investigate the effects of diurnal rhythm on spatial learning and memory, the water maze was used. All mice were subjected to the water maze for 4 days to examine acquisition. The results show there were no differences in escape latency (p=0.24, F(1,22)=1.45) and travel distance (p=0.85, F(1,22)=0.03) in the initial test, nor the retest three months later (escape latency, p=0.53, F(1,22)=0.39; travel distance, p=0.65, F(1,22)=0.2) (Fig.3A). Seven days after the last training, the escape platform was removed, and mice were subjected to the water maze, and spatial memory was evaluated. There were no significant differences detected between the active group and inactive group for the initial test (time spent in target zone, p=0.82, t(22)=0.22; platform crosses, p=0.06, t(22)=1.9), nor the retest three months later (time spent in target zone, p=0.21, t(22)=1.28; platform crosses, p=0.22, t(22)=1.25) (Fig.3B). These data suggest that there are no obvious differences detected in spatial learning and memory between mice tested in active or inactive period.

Effects of diurnal phase on spatial learning and memory. (A) During water maze training, there is no difference in escape latency or travel distance between active and inactive groups, neither in the retest 3months later. (B) For the memory retrieval of the water maze, there is no significant difference detected in time in target zone or platform crosses 7days after the last training, nor in the retest. Blue circles: male mice; Red circles: female mice.

Next, to better assess whether the circadian period affects other types of cognitive behavior, we conducted T-maze, contextual fear, and active avoidance tests. For T-maze alternation, the results show there were no differences in percentage of correct choices in the initial test (p=0.79), nor the second test three months later (p=0.8) (Fig.4A). For contextual fear conditioning, there were no differences detected in freezing time during the pre-shock session (p=0.07, t(22)=1.88), and there was no difference in freezing time detected in the test session 24h after the shock (p=0.15, t(22)=1.47) (Fig.4B). Three months later, all mice were subjected to the footshock chamber again. Mice tested in the active phase exhibited an increase in freezing time during the pre-shock session (p=0.007, t(22)=2.94), but no differences during the test session (p=0.21, t(22)=1.27), suggesting mice tested in the active phase show better long-term memory of the footshock chamber (Fig.4B). For active avoidance, mice tested in the active period exhibited higher escape success rate than those tested in the inactive phase (p=0.0028, t(22)=3.36), suggesting that mice learn active avoidance better during the active phase. Three months later all the mice were subjected to active avoidance testing again, and the results show there was no significant difference (p=0.25, t(22)=1.15) (Fig.4C). Clock genes have been extensively studied and show circadian expression in the brain11,12. To further confirm physiological gene expression pattern of active and inactive periods in these mice, three days after the last behavioral test, we harvested hippocampal tissue for clock gene expression four hours after lights on/off. Our results show that hippocampal tissue harvested in the active period (Zeitgeber Time 16, ZT16) exhibit higher expression of Per1 (p=0.0001, t(8)=6.74) and Per2 (p=0.0013, t(9)=4.57), and lower expression of Bmal1 (p=0.0049, t(9)=3.69) compared to tissue harvested during the inactive phase (Zeitgeber Time 4, ZT4) (Fig.4D). These results confirm the mice had differential gene expression between active and inactive phase.

Effects of diurnal phase on T-maze, contextual fear, active avoidance, expression of clock genes. (A) In the T-maze test, there is no significant difference in the percentage of correct choices observed influenced by diurnal rhythm, nor in the retest. (B) For the contextual fear conditioning, there is no difference in freezing time during the pre-shock session between active and inactive groups. Twenty-four hours after the footshock, both active and inactive groups show increased freezing time during the test session, but no significant difference was detected. Three months later, mice tested in active phase exhibited a higher percentage of freezing in the pre-shock session, but no difference in freezing time during the test session. (C) For active avoidance, mice tested in the active phase feature higher escape success rates compared to mice tested in the inactive phase. In the retest, no significant difference is detected. (D) The phase differences in expression of clock genes (Per1, Per2, and Bmal1) in the hippocampus at ZT4 (inactive group) and ZT16 (active group). Blue circles: male mice; Red circles: female mice.

In order to determine whether differences in sex could be contributing to our results, for each measure we compared a model in which phase predicted the behavior to a model that in addition contained sex as a predictor. We applied a Bonferroni 5% corrected threshold of 0.00156 to take into account the fact that we ran 32 tests (0.05/32=0.00156). Our figures show results for males and females where males are colored blue and females colored red. We found two behavioral results exceeded the 5% threshold; time spent in open arms (p=0.00017) and travel distance (p=0.0012) of elevatedO-maze at 20weeks in our analysis. However, the small sample size and consequent low power means we cannot exclude the presence of a sex difference. Table 1 provides a summary of the sex difference analyses.

Read the original here:
Influence of diurnal phase on behavioral tests of sensorimotor performance, anxiety, learning and memory in mice | Scientific Reports - Nature.com

Crichton's novel "Jurassic Park," published in 1990, provided the source concepts for the entire "Jurassic Park" universe. The authorhas had over a dozen of his novels adapted for film, including "The Andromeda Strain," "The Terminal Man," and "Coma." As with all his projects, Crichton did a great deal of hard research before putting pen to paper on "Jurassic Park" and its sequel, "The Lost World" (via Smithsonian Magazine).

While undoubtedly taking outrageous liberties for artistic effect, there is some serious science hiding behind (or at least inspiring) the movies. Genetic engineering, gene splicing, DNA editing, and cloning are all thriving disciplines in the 21st century. "De-extinction" efforts to bring back long-dead species may be closer to success than many people realize (via The New York Times), and corporate ownership of genetic information, or "biobanking," is a genuine bioethical controversy.

The scientific basis for a theme park of dinosaur clones may be a stretch, but the original movie did employ reputable dinosaur experts as advisors (via ThoughtCo). One ongoing controversy among paleontologists involving the true nature of the T. Rex even made it on-screen in 1997's "The Lost World: Jurassic Park."

Original post:
The Real-Life Paleontology Feud That Made It Into The Lost World: Jurassic Park - Looper

GAINESVILLE, Fla. Meditating for a few minutes each day may be the first step in helping the body fight off cancer and viruses like COVID-19, a new study reveals. A team from the University of Florida found that meditation and yoga programs, or Inner Engineering practices, dramatically boost the bodys immune system.

Their worked focused on patients practicing these techniques intensely meditating for over 10 hours a day for over a week. Meditation retreats have become increasingly popular over the past few years as more people look to take a break from their busy schedule and spend time alone with their thoughts.

While the positive effects of meditation are well documented, far less is known about how it affects biological processes at the molecular level. Now, scientists found spending a week in silent meditation appears to hold genetic benefits that help combat life-threatening diseases.

Researchers add these participants also followed a vegan diet and a regular sleep schedule during the retreat, but those healthy practices did not have the same effect as meditation. Study author Dr. Vijayendran Chandran began practicing meditation for 21 minutes a day after his wife suggested he give it a chance.

I was just trying to be open-minded. I tried it and it worked really well. My clarity and focus were improved. I just felt great, Chandran recalls in a university release.

The study involved 106 people embarking on a meditation retreat at the Isha Institute of Inner-Sciences in Tennessee, in 2018. During the tightly controlled retreat, participants remained in silence for eight days, meditated over 10 hours a day, ate only vegan meals, and maintained a healthy amount of sleep each night.

Researchers collected blood samples five to eight weeks beforehand, immediately before and after the retreat, and three months later. They discovered genetic differences between samples taken before and after the intense meditation retreat. Specifically, 220 genes linked to the bodys immune system were more active after participants attended the Inner Engineering meditation retreat. This included 68 genes that have a connection to interferon signaling, which helps the body combat viruses and cancer.

What we found was that multiple genes related to the immune system were activated dramatically when you do Inner Engineering practices, Dr. Chandran reports. This is the first time anyone has shown that meditation can boost your interferon signaling. It demonstrates a way to voluntarily influence the immune system without pharmaceuticals.

Recent studies have also found interferon signaling imbalances in patients with severe cases of COVID-19 and multiple sclerosis (MS). The researchers compared participants interferon gene activity with COVID patients and found stark differences. Mediation activated 97 percent of the virus fighting interferon genes, compared to 76 percent in mild COVID patients and 31 percent in severe cases.

Likewise, meditation proved to be more beneficial than traditional interferon treatments for MS patients.

Dr. Chandran notes that, taken together, the findings support using meditation to potentially improve multiple health conditions. Study authors add they need conduct more studies on this and hope to determine if less intense meditation regimens over a longer term might produce similar beneficial immune system effects.

The findings are published in the Proceedings of the National Academy of Sciences.

South West News Service writer Tom Campbell contributed to this report.

Original post:
Meditating each day activates genes that fight off cancer and viruses like COVID-19 - Study Finds

Dr Shahid Jameel says that hospitals look better prepared and equipped than in the Second Wave, but the biggest challenge for them would be healthcare workers getting infected.(Illustration: Suneesh Kalarickal)

Dr Shahid Jameel is a leading Indian virologist and academic. Currently, he is the Sultan Qaboos bin Said Fellow at Oxford Centre for Islamic Studies and Research Fellow, Green Templeton College, University of Oxford. Dr Jameel has been Chief Executive Officer of the Wellcome Trust/DBT India Alliance,an independent public charity that funds research in health and biomedical sciences in India,since April 2013.

Prior to joining the India Alliance, he was Group Leader of Virology at the International Centre for Genetic Engineering and Biotechnology, New Delhi, for over 25 years.He did his PhD in Biochemistry from Washington State University (USA) and his postdoctoral work in Molecular Virology from the University of Colorado Medical School (USA).

Last May, Dr Jameel had resigned as head of India's virus genome sequencing group. In an opinionpiece written for the New York Times, hesaid that"scientists were facing stubborn-resistance to evidence-based policy-making".

In an interview with Moneycontrol, Dr Jameel looks at various aspects of the coronavirus pandemic, Omicron and new variants that may crop up. Excerpts from the interview:

What is the most likely scenariofor the spreadof the coronavirus over the next two months?

The cases in India are already rising very quickly - about 195,000 cases were reported on January 11. Over the next 2-4 weeks there would possibly be a peak and then cases will decline fairly quickly, if we experience South Africa's trajectory. The Indian Institute of Science (IISc) and the Indian Statistical Institute (ISI) (IISc-ISI model) for India predict a best-case scenario peaking around 300,000 cases per day in another week. The worst-case scenario shows a peak of around 1 million daily cases in the last week of January. What follows will depend upon what percentage of India is susceptible. By early March, the case numbers should be down to baseline. Severe disease and hospitalisation is projected to be lower, with the best case scenario predicting the need for about 170-180,000 beds per day at peak.

Read also: Coronavirus Omicron Live Updates.

What becomes of economic activity?

Economic activity will suffer as fewer people will go to work, markets, restaurants, etc either due to Covid symptoms and isolation or due to reduced opening times, among other issues.

What kind of activities can be permitted? Return to restaurants, cinemahalls, malls and traveling, both local and global?

Any indoor activity that requires one to remove a mask should be restricted at this time.

What about manufacturing?

Manufacturing with reduced workforce at any time, using shifts, etc can proceed with strict guidance to follow proper masking.

What should peoples' activitiesbe in the next month or so?

(a) Don't panic; (b) Continue to use masks indoors and in crowded outdoor locations; (c) restrict indoor activities, especially those that require taking off the mask; (d) improve ventilation; (e) carry on with your life with common sense.

What should organisations do under the circumstances concerning employees and workplace?

They need to provide better ventilation at the workplace; provide good masks to all employees and ensure compliance; invest in the health of employees; generously use the work from home (WFH) option and reduce staff by working in shifts.

When will India reach the endemicstage and by when can companies bring back employees into their workplace?

Very hard to say when the endemic stage will be reached. If people are fully vaccinated, they may get infected but will not have severe disease even if fresh variants come up. Vaccination is critical. Get used to this way of life for the next few years. Companies should invest in people instead of letting them go and become more flexible in their approach to work.

What do you say about Covid and hospitalisation data in India?

So far it looks like hospital admissions in India are under control. Hospitals are also better prepared and equipped with medicines, oxygen, ventilators, and so on, compared to the Second Wave. The biggest challenge for hospitals is healthcare workers getting infected. Even if they have asymptomatic/mild infection, they have to be isolated and that puts pressure on the remaining workforce.

The Omicron was supposed to be mild. Do you believe that is the case? Some reports suggest a mounting death toll in the country and acrossthe world.

The evidence so far is that the infection is milder than Delta, especially in people who have received two vaccine doses or have hybrid (infection-vaccination) immunity. Those in hospital are largely the unvaccinated, the elderly and people with comorbidities.

But to think that Omicron is a 'natural vaccine is not correct. By that it is implied that one can get infected on purpose to be protected in future. We still don't know (a) how individuals will respond due to age or underlying health conditions; and (b) effects of "long Covid" even in those who get mild disease.

See original here:
Virologist Dr Shahid Jameel on COVID-19: "We have to get used to this way of life for the next few... - Moneycontrol.com

Hasan Sojib | Published: January 10, 2022 13:23:23 | Updated: January 13, 2022 00:07:30

A Memorandum of Understanding (MoU) has been signed between the Center for Nanotechnology, Department of Natural Sciences, Coppin State University, USA and the Department of Biotechnology and Genetic Engineering, Jahangirnagar University (JU).

The MoU was signed at 11 am on Sunday (January 9) at the new registrar building of the university.

The University treasurer Professor Rasheda Akhter on behalf of Jahangirnagar University and Professor Dr Jamal Uddin from Coppin State University signed the MoU.

The MoU states that the universities will continue to work on enhancing scientific and academic understandings. They will also cooperate with each other in research.

Later, the 'International Biotechnology Seminar-2022' was held in the Senate Room of the University. Professor Jamal Uddin joined the seminar.

The chief guest of the seminar, vice-chancellor of JU, Professor Farzana Islam said, "The progress of biotechnology and genetic engineering is apparent in our country now. Our teachers and students are working their level best to uplift the department to a better place."

"As a result, even during this ominous period amid Corona, a guest came to us from the United States. He inspired us a lot with his works. An MoU has also been signed with us. I hope this relationship between the two universities will lead to much better research," the VC remarked.

The convener of the seminar, Professor Sharif Hossain, said, "Biotechnology and nanotechnology are playing an important role in various aspects of human life in the 21st century. These are used in many branches of agriculture, industry and science."

Prof. Sharif also said that the use of nanotechnology has grown exponentially in recent times.

"From cosmetics to the blue economy, nanotechnology is everywhere. I believe that the agreement that is being established with the Department of Biotechnology will enable us to do a lot of research works."

Along with the treasurer, the seminar was attended by Professor Abdul Jabbar Hawladar, President of the Department of Biotechnology and Genetic Engineering, Professor Umme Salma Zohra, Professor Mohammad Shahedur Rahman and others.

Go here to read the rest:
MoU signed between JU and Coppin State University of US - The Financial Express

This report provides a deep insight into the global CRISPR Cas9 market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porters five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the CRISPR Cas9 market in any manner.

The business intelligence report on CRISPR Cas9 market entails a comprehensive assessment of the factors impacting the industry dynamics over the estimated timeline. It focusses on the major growth catalysts and remunerative opportunities that could boost the profitability ratio of the market during the projected timeframe. It also includes the constraints and challenges to the industry growth along with strategies to subdue their relevant impacts.

Request Sample Copy of this Report @ https://www.getnewsalert.com/request-sample/2718

Furthermore, the report contains an exclusive study of the various market segmentations to assist new investors and shareholders in identifying areas with high revenue potential. Additionally, it encompasses case studies on the COVID-19 pandemic to offer a clearer understanding of the changing business landscape.

Key highlights from COVID-19 impact analysis:

A gist of the regional landscape:

Other highlights from the CRISPR Cas9 market report:

An overview of information related to geographic indicators included in the report:

What are the market factors that are explained in the report?

Request Customization on This Report @ https://www.getnewsalert.com/request-for-customization/2718

Read more from the original source:
CRISPR Cas9 Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2026 - Get News Alert

As of January 1, 2022, food thats been previously known as a GMO or genetically engineered food will have a new Bioengineered (BE) label. If the term leaves you confused or searching your favorite online encyclopedia, youre not alone. Critics of the new legislation are concerned that the new GMO rebrand may cause even more confusion and less transparency than its predecessor.

The Center for Food Safety,a San Franciscobased nonprofit whose stated mission is to protect the earth from harmful impacts of industrial agriculture, has already filed a lawsuit asking a federal court to strike down this and other labeling laws instituted by the Trump administration.

Consumers have fought for decades for their right to know whats in their food and how its produced, stated Meredith Stevenson, an attorney for the center, in a press release. But instead of providing meaningful labeling, USDAs final rules will only create more uncertainty for consumers, retailers, and manufacturers.

Most consumers are familiar with the term that "bioengineered" replaced GMO, which stands for genetically modified organism. A GMO is a plant, animal, microorganism or other organism whose genetic makeup has been modified in a laboratory using genetic engineering or transgenic technology, which results in combinations of plant, animal, bacterial, and virus genes that dont occur in nature or through traditional crossbreeding methods, according to the Non-GMO Project, a nonprofit that aims to inform the public about what is in their food and how to access non-GMO choices (and whose verification seal has been one of the most prominent ways to identify non-GMO packaged foods).

The definition of a bioengineered food is quite similar. According to the United States Department of Agriculture (USDA), a bioengineered (BE) food is food that contains genetic material that has been modified through certain laboratory techniques and for which the modification could not be obtained through conventional breeding or found in nature. Despite this definition, some exemptions in the BE labeling mandate mean that many foods that contain GMOs by current standards may not have to be labeled that way under the new guidelines (see items 3 and 4 below).

Keep reading to learn what a BE label means for you and your health, and how to spot foods that arent bioengineered.

RELATED: What Is a Black Box Warning for a Drug?

These labels both the Non-GMO Project label and the new Bioengineered label are marketing tools, says Peter Goldsbrough, PhD, a professor of botany and plant pathology at Purdue University in West Lafayette, Indiana, who specializes in GMOs and GMO educational practices. If you read the USDA position on this, its clear the labels are for marketing purposes, to let consumers know what theyre buying, says Dr. Goldsbrough. Unfortunately, this new terminology may confuse people. Most consumers are already unclear about what GMO means, and this will probably add to that, he says.

Still, the new labeling doesnt change anything about the composition of the food we're purchasing and eating, Goldsbrough says. Humans have been genetically modifying crops using selection and breeding since agriculture began, over 11,000 years ago. The types of food ingredients that have been genetically engineered or bioengineered are going to remain the same, he says, and there will be new foods added as the technology continues to develop.

I think one of the most important things that people need to know is that there are no health safety concerns about consuming GMO foods, says Goldsbrough. Thats the position of the U.S. Food and Drug Administration [FDA], the World Health Organization, the European Food Safety Agency all these agencies have concluded that theres no safety concerns with the genetically modified foods that are on the market today. The presence or absence of a non-BE or Non-GMO label doesnt mean that a food is healthy or unhealthy, he adds.

RELATED: Why Are Some Food Additives That Are Banned in Europe Still Used in the U.S.?

Food items that contain ingredients that are considered highly refined such as sugar and corn oil dont require bioengineering disclosure, so they'll have no BE label. For example, when genetically modified corn is processed to make oil or corn syrup, the resulting highly refined ingredient shows no detectable DNA from the bioengineered crop, and therefore is not required to bear a bioengineered label. Excluding foods that use these ingredients makes the number of foods that will have a BE label considerably smaller, says Goldsbrough. An awful lot of things contain corn or soybean oil.

Food industry and food advocacy groups are divided on the omission of these products, according to the Center for Science in the Public Interest, but the USDA decided that an ingredient is not a bioengineered food if the genetically modified material is undetectable, says Goldsbrough.

Advocates for disclosure claim that there is evidence that the highly refined ingredients contain genetic material, even if its not detectable. Many products made with newer GMO technologies such as CRISPR, TALEN, and RNAi are currently untestable and therefore dont require a BE label, according to the Non-GMO Project.

Even though its not required, some companies may choose to disclose that they are using those highly refined ingredients that come from genetically modified crops, according to the USDA. These foods may state Derived From Bioengineering or Ingredients Derived From a Bioengineered Source on their label.

Products made with meat, poultry, or eggs are exempt from the BE labeling law. Multi-ingredient products in which meat, poultry, or eggs are the first ingredient are also exempt, even if other ingredients in the product do have detectable levels of modified genetic material.

The USDA gives the example of a can of pork stew that also contains genetically modified sweet corn. If pork is the main ingredient and listed first on the ingredient panel, the can of stew wouldnt be required to have a BE label because meat is exempt from the labeling requirement. If the stew lists water, broth, or stock as the first ingredient and pork as the second, that would also not require a BE label because water, stock, and broth dont count. The only way the stew would earn a BE label is if there was more corn than pork in the stew.

Because the new bioengineered definition leaves out foods that contain the highly refined oils and sugars that are derived from genetically modified food as well as multi-ingredient foods (such as the pork stew example), the position of the Non-GMO Project is that the Bioengineered Food labeling law is ineffective at finding GMOs and avoiding GMOs, largely because of restrictions, loopholes, and exemptions.

Foods that have detectable modified genetic material and are considered bioengineered will be identified on their packaging or label with one or more of the following:

The Non-GMO Project label, which depicts an orange butterfly on a green blade of grass, will continue to be used on a voluntary basis by companies that wish to adhere to the groups more stringent standards.

RELATED: 10 Common Food and Medication Interactions to Avoid

Products that sport a USDA Certified Organic label must be free of GMO and bioengineered ingredients. This was decided because the organic food industry does not want to use foods that are genetically modified, and its a way of distinguishing their brand from conventional foods, says Goldsbrough. So for consumers who want to avoid bioengineered foods, seeking out certified organic foods is probably the simplest and most reliable way to do that. Although there isnt evidence that GMO foods are harmful, its consumer choice, he says. If people wish to avoid genetically modified foods, this is one way to go about that.

In general, the foods that are most likely to contain GMOs or bioengineered ingredients are those that are the most processed. If you go into the sections where foods are more processed and use corn or soybean ingredients, unless theyre organic, they are more likely to contain items that are derived from a bioengineered crop plant, says Goldsbrough. If you tend to shop for fresh produce, meats, and dairy, on the other hand, those are less likely to be genetically modified. Ultimately, it's one more reason to keep your diet as minimally processed as possible.

See the original post:
6 Things You Need to Know About the New GMO Food Label - Everyday Health

Dublin-based Horizon Therapeutics is expanding in Montgomery County, Md., on the heels of last years acquisition of Gaithersburg, Md.-based Viela Bio, another biotech company.

Horizon Therapeutics has signed a long-term, 192,000-square-foot lease at Alexandria Center Traville Gateway, a planned 500,000-square-foot life sciences complex being developed by Alexandria Real Estate Equities on 18 acres in Rockville, Md.

The global life sciences company will occupy an entire building, which is the first one under construction at the complex and is scheduled to be ready sometime in 2023.

The opportunity to custom build a state-of-the-art facility that suits our current and future [research and development] and technical operations needs was attractive, Geoffrey M. Curtis, an executive vice president in corporate affairs at Horizon Therapeutics, told CO.

The company has operated out of approximately 32,000 square feet in two buildings at 1 MedImmune Way in Gaithersburg since its Viela Bio acquisition in March and will be relocating when the space is available.

The new space will serve as our East Coast R&D and technical operations hub and will allow for all employees and functions to be in one building, Curtis said.

The new facility will also allow Horizon Therapeutics to quadruple its current Maryland footprint and better drive its continued efforts to develop new medicines for patients with rare, autoimmune and severe inflammatory diseases, he noted.

Maryland Gov. Larry Hogan released a statement praising the news and championed the life sciences sector in the state.

It is a testament to our outstanding business climate and wealth of resources that we have seen so many life sciences companies expand and add thousands of new jobs in our state in recent years, he said.

Maryland is considered a top 4 cluster nationally by Genetic Engineering & Biotechnology News annual ranking of the nations top 10 life sciences clusters, with Montgomery County responsible for a lot of the demand and growth.

Horizon Therapeutics was represented by CBRE in the transaction. The developers were represented in-house.

Requests for comment from the development team and CBRE were not immediately returned.

Keith Loria can be reached at Kloria@commercialobserver.com.

Follow this link:
Biotech Giant Horizon Therapeutics Expanding in Montgomery County - Commercial Observer